AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- An RTS,S+TRAP malaria vaccine, formulated in the AS02A adjuvant system, appears promising for immunization of infants.
According to a study from the United States, "Malaria vaccine RTS,S combined with thrombospondin-related anonymous protein (TRAP) and formulated with AS02A (RTS,S+TRAP/AS02A) is safe and immunogenic in adult humans and rhesus monkeys (Macaca mulatta). Here, RTS,S+TRAP/AS02A was administered on a 0-, 1-, and 3-month schedule to three cohorts of infant monkeys, along with adult comparators. Cohort I evaluated 1/5, 1/2, and full adult doses, with the first dose administration at one month of age; cohort 2 monkeys received full adult doses, with the first dose administration at 1 versus 3 months of age; and, cohort 3 compared infants gestated in mothers with or without previous RTS,S/AS02A immunization."
"Immunization site reactogenicity was mild," stated Douglas S. Walsh at the Eisenhower Army Medical Center in the U.S. and collaborators throughout the world. "Some infants, including the phosphate-buffered saline only recipient, developed transient iron-deficiency anemia, which is considered a result of repeated phlebotomies. All RTS,S+TRAP/AS02A regimens induced vigorous antibody responses that persisted through 12 weeks after the last vaccine dose. Modest lymphoproliferative and ELISPOT (interferon-gamma and ...
Source: HighBeam Research, RTS,S+TRAP malaria vaccine shows promise for infant immunization.